{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05724693",
            "orgStudyIdInfo": {
                "id": "AT-03A-010"
            },
            "organization": {
                "fullName": "Atea Pharmaceuticals, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function",
            "officialTitle": "A Phase 1, Multicenter, Open-Label, Parallel-Group, Pharmacokinetic Single Dose Study of Bemnifosbuvir (AT-527) in Adult Subjects With Normal and Impaired Hepatic Function",
            "therapeuticArea": [
                "Other"
            ],
            "study": "study-of-bemnifosbuvir-in-subjects-with-normal-and-impaired-hepatic-function"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-02",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-01-30",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-03-29",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-03-29",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-01-24",
            "studyFirstSubmitQcDate": "2023-02-02",
            "studyFirstPostDateStruct": {
                "date": "2023-02-13",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-02-01",
            "lastUpdatePostDateStruct": {
                "date": "2024-02-02",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Atea Pharmaceuticals, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "To Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Bemnifosbuvir After a Single Dose"
        },
        "conditionsModule": {
            "conditions": [
                "Healthy Volunteer",
                "Hepatic Impairment"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 40,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Group 1 -Mild Hepatic Impairment",
                    "type": "EXPERIMENTAL",
                    "description": "Drug: single dose Bemnifosbuvir (BEM)",
                    "interventionNames": [
                        "Drug: Bemnifosbuvir (BEM)"
                    ]
                },
                {
                    "label": "Group 2-Moderate Hepatic Impairment",
                    "type": "EXPERIMENTAL",
                    "description": "Drug: single dose Bemnifosbuvir (BEM)",
                    "interventionNames": [
                        "Drug: Bemnifosbuvir (BEM)"
                    ]
                },
                {
                    "label": "Group 3 - Healthy Subjects matching mild and moderate impairment groups",
                    "type": "EXPERIMENTAL",
                    "description": "Drug: single dose Bemnifosbuvir (BEM)",
                    "interventionNames": [
                        "Drug: Bemnifosbuvir (BEM)"
                    ]
                },
                {
                    "label": "Group 4 - Severe Hepatic Impairment",
                    "type": "EXPERIMENTAL",
                    "description": "Drug: single dose Bemnifosbuvir (BEM)",
                    "interventionNames": [
                        "Drug: Bemnifosbuvir (BEM)"
                    ]
                },
                {
                    "label": "Group 5 - Normal hepatic function matching severe impairment group",
                    "type": "EXPERIMENTAL",
                    "description": "Drug: single dose Bemnifosbuvir (BEM)",
                    "interventionNames": [
                        "Drug: Bemnifosbuvir (BEM)"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Bemnifosbuvir (BEM)",
                    "description": "Day 1: A single dose of BEM will be administered",
                    "armGroupLabels": [
                        "Group 1 -Mild Hepatic Impairment",
                        "Group 2-Moderate Hepatic Impairment",
                        "Group 3 - Healthy Subjects matching mild and moderate impairment groups",
                        "Group 4 - Severe Hepatic Impairment",
                        "Group 5 - Normal hepatic function matching severe impairment group"
                    ],
                    "otherNames": [
                        "AT-527"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Pharmacokinetics (PK) of BEM Maximum plasma concentration (Cmax)",
                    "timeFrame": "Day 1"
                },
                {
                    "measure": "Pharmacokinetics (PK) of BEM Area under the plasma concentration-time curve (AUC)",
                    "timeFrame": "Day 1"
                },
                {
                    "measure": "Pharmacokinetics (PK) of BEM AUC",
                    "timeFrame": "Day 1"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Must agree to use two methods of birth control from Screening through 90 days after administration of the last dose of study drug\n* Females must have a negative pregnancy test at Screening and prior to dosing\n* BMI of 18.5 to 42.0 kg/m2\n* Willing to comply with the study requirements and to provide written informed consent\n\nSubjects with Normal Hepatic Function (Groups 3 and 5):\n\n* Medically healthy, in the opinion of an Investigator\n* Must match by gender, age (\u00b1 10 years), and BMI (\u00b1 20%) to the pooled mean values of subjects with hepatic impairment\n\nHepatic Impaired Subjects (Groups 1, 2, and 4):\n\n* Considered stable for at least 1 month prior to Screening, as per the judgement of an Investigator\n* When applicable, presence of mild hepatic impairment (Child-Pugh Class A: score of 5 to 6), moderate hepatic impairment (Child-Pugh Class B: score of 7 to 9) or severe hepatic impairment (Child-Pugh Class C: score of 10 to 15). Hepatic impairment should be stable for at least 1 month prior to Screening\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding\n* Infected with hepatitis B virus, hepatitis C virus, HIV or COVID-19\n* Abuse of alcohol or drugs\n* Use of other investigational drugs within 28 days of dosing\n* Other clinically significant medical conditions or laboratory abnormalities\n\nHepatic Impaired Subjects (Groups 1, 2, and 4):\n\n* Currently undergoing any method of dialysis\n* History of liver transplant\n* Presence of poorly controlled Type 1 or Type 2 diabetes as defined by Hemoglobin A1c (HbA1c) \\> 10%\n* Evidence of hepatic carcinoma presence at Screening",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "80 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Atea Study Clinical Trials Administrator",
                    "role": "CONTACT",
                    "phone": "888-481-1607",
                    "email": "AteaClinicalTrials@ateapharma.com"
                }
            ],
            "locations": [
                {
                    "facility": "Atea Study Site Orlando Clinical Research Center",
                    "status": "RECRUITING",
                    "city": "Orlando",
                    "state": "Florida",
                    "zip": "32809",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Atea Study Site (OCRC)",
                            "role": "CONTACT",
                            "phone": "888-481-1607",
                            "email": "AteaClinicalTrials@ateapharma.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 28.53834,
                        "lon": -81.37924
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        }
    },
    "hasResults": false
}